JPWO2021155380A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021155380A5
JPWO2021155380A5 JP2022547063A JP2022547063A JPWO2021155380A5 JP WO2021155380 A5 JPWO2021155380 A5 JP WO2021155380A5 JP 2022547063 A JP2022547063 A JP 2022547063A JP 2022547063 A JP2022547063 A JP 2022547063A JP WO2021155380 A5 JPWO2021155380 A5 JP WO2021155380A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022547063A
Other languages
Japanese (ja)
Other versions
JP2023512297A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/016104 external-priority patent/WO2021155380A1/en
Publication of JP2023512297A publication Critical patent/JP2023512297A/en
Publication of JPWO2021155380A5 publication Critical patent/JPWO2021155380A5/ja
Pending legal-status Critical Current

Links

Claims (23)

二重特異性分子であって、A bispecific molecule,
（１）ｓｃｆｖフォーマットの第１の抗ＤＬＬ３抗体の抗原結合断片と、ｓｃｆｖフォーマットの抗ＣＤ３抗体の抗原結合断片とを含む、第１のポリペプチド鎖であって、(1) a first polypeptide chain comprising an antigen-binding fragment of a first anti-DLL3 antibody in scfv format and an antigen-binding fragment of an anti-CD3 antibody in scfv format,
前記第１の抗ＤＬＬ３抗体の抗原結合断片は、配列番号７に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１４に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２７に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３１に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４０に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号４７に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む、第１のポリペプチド鎖、The antigen-binding fragment of the first anti-DLL3 antibody has a heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 7, a heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 14, and a heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 27. A heavy chain variable region comprising a heavy chain CDR3 comprising at least the amino acid sequence; a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 31; a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 40; and SEQ ID NO: 47. a first polypeptide chain comprising a light chain variable region comprising a light chain CDR3 comprising at least the amino acid sequence set forth in
（２）第２の抗ＤＬＬ３抗体の重鎖を含む第２のポリペプチド鎖、及び(2) a second polypeptide chain comprising a heavy chain of a second anti-DLL3 antibody, and
（３）第２の抗ＤＬＬ３抗体の軽鎖を含む第３のポリペプチド鎖、(3) a third polypeptide chain comprising a light chain of a second anti-DLL3 antibody;
の３つのポリペプチド鎖を含む、二重特異性分子。A bispecific molecule containing three polypeptide chains. 前記第２のポリペプチド鎖は、第２の抗ＤＬＬ３抗体の重鎖を含み、前記第２の抗ＤＬＬ３抗体の重鎖は、配列番号６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２４に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域を含み、かつThe second polypeptide chain comprises a heavy chain of a second anti-DLL3 antibody, and the heavy chain of the second anti-DLL3 antibody comprises a heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 6, SEQ ID NO: a heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 16, and a heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 24, and
前記第３のポリペプチド鎖は、第２の抗ＤＬＬ３抗体の軽鎖を含み、前記第２の抗ＤＬＬ抗体の軽鎖は、配列番号３３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号４９に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域を含む、請求項１に記載の二重特異性分子。The third polypeptide chain comprises a light chain of a second anti-DLL3 antibody, and the light chain of the second anti-DLL3 antibody comprises a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 33, SEQ ID NO: 49. The bispecific molecule according to claim 1, comprising a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 43, and a light chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 49. 前記第１のポリペプチド鎖中の抗ＣＤ３抗体の抗原結合断片は、配列番号２５６を含む重鎖可変領域及び配列番号２６１を含む軽鎖可変領域を含む、請求項１に記載の二重特異性分子。2. The bispecific antibody of claim 1, wherein the antigen-binding fragment of the anti-CD3 antibody in the first polypeptide chain comprises a heavy chain variable region comprising SEQ ID NO: 256 and a light chain variable region comprising SEQ ID NO: 261. molecule. 前記第１のポリペプチド鎖中の第１の抗ＤＬＬ３抗体の抗原結合断片は、配列番号７２を含む重鎖可変領域及び配列番号７６を含む軽鎖可変領域を含み、The antigen-binding fragment of the first anti-DLL3 antibody in the first polypeptide chain comprises a heavy chain variable region comprising SEQ ID NO: 72 and a light chain variable region comprising SEQ ID NO: 76;
前記第１のポリペプチド鎖中の抗ＣＤ３抗体の抗原結合断片は、配列番号２５６を含む重鎖可変領域及び配列番号２６１を含む軽鎖可変領域を含み、The antigen-binding fragment of the anti-CD3 antibody in the first polypeptide chain comprises a heavy chain variable region comprising SEQ ID NO: 256 and a light chain variable region comprising SEQ ID NO: 261;
前記第２のポリペプチド鎖中の第２の抗ＤＬＬ３抗体の重鎖は、配列番号５８に記載のアミノ酸配列を含み、かつThe heavy chain of the second anti-DLL3 antibody in the second polypeptide chain comprises the amino acid sequence set forth in SEQ ID NO: 58, and
前記第３のポリペプチド鎖中の第２の抗ＤＬＬ３抗体の軽鎖は、配列番号７８に記載のアミノ酸配列を含む、請求項１に記載の二重特異性分子。78. The bispecific molecule of claim 1, wherein the light chain of the second anti-DLL3 antibody in the third polypeptide chain comprises the amino acid sequence set forth in SEQ ID NO:78. 前記第１のポリペプチド鎖は、配列番号３４７に記載のアミノ酸配列を含み、前記第２のポリペプチド鎖は、配列番号２７６に記載のアミノ酸配列を含み、前記第３のポリペプチド鎖は配列番号２９７に記載のアミノ酸配列を含む、請求項１に記載の二重特異性分子。The first polypeptide chain comprises the amino acid sequence set forth in SEQ ID NO: 347, the second polypeptide chain comprises the amino acid sequence set forth in SEQ ID NO: 276, and the third polypeptide chain comprises the amino acid sequence set forth in SEQ ID NO: 276. Bispecific molecule according to claim 1, comprising the amino acid sequence according to 297. 請求項１に記載の二重特異性分子を含む、癌治療において使用するための医薬組成物。A pharmaceutical composition for use in cancer therapy comprising a bispecific molecule according to claim 1. 前記癌が、乳癌、肺癌、腎癌、膀胱癌、尿路癌、尿道癌、陰茎癌、外陰癌、膣癌、子宮頸癌、結腸癌、卵巣癌、前立腺癌、膵臓癌、胃癌、脳癌、頭頸部癌、皮膚癌、子宮癌、精巣癌、食道癌及び肝臓癌からなる群から選択される、請求項６に記載の医薬組成物。The cancer is breast cancer, lung cancer, kidney cancer, bladder cancer, urinary tract cancer, urethral cancer, penile cancer, vulvar cancer, vaginal cancer, cervical cancer, colon cancer, ovarian cancer, prostate cancer, pancreatic cancer, stomach cancer, brain cancer. , head and neck cancer, skin cancer, uterine cancer, testicular cancer, esophageal cancer, and liver cancer. 前記癌が、小細胞肺癌（ＳＣＬＣ）又は神経内分泌起源の癌である、請求項６に記載の医薬組成物。7. The pharmaceutical composition according to claim 6, wherein the cancer is small cell lung cancer (SCLC) or a cancer of neuroendocrine origin. 癌治療のための医薬の製造における、請求項１に記載の二重特異性分子の使用。Use of a bispecific molecule according to claim 1 in the manufacture of a medicament for the treatment of cancer. 前記癌が、乳癌、肺癌、腎癌、膀胱癌、尿路癌、尿道癌、陰茎癌、外陰癌、膣癌、子宮頸癌、結腸癌、卵巣癌、前立腺癌、膵臓癌、胃癌、脳癌、頭頸部癌、皮膚癌、子宮癌、精巣癌、食道癌及び肝臓癌からなる群から選択される、請求項９に記載の使用。The cancer is breast cancer, lung cancer, kidney cancer, bladder cancer, urinary tract cancer, urethral cancer, penile cancer, vulvar cancer, vaginal cancer, cervical cancer, colon cancer, ovarian cancer, prostate cancer, pancreatic cancer, stomach cancer, brain cancer. , head and neck cancer, skin cancer, uterine cancer, testicular cancer, esophageal cancer and liver cancer. 前記癌が、小細胞肺癌（ＳＣＬＣ）又は神経内分泌起源の癌である、請求項９に記載の使用。10. The use according to claim 9, wherein the cancer is small cell lung cancer (SCLC) or a cancer of neuroendocrine origin. 請求項１に記載の二重特異性分子を含む、ＤＬＬ３発現細胞に対するＴ細胞の活性化において使用するための、医薬組成物。A pharmaceutical composition comprising a bispecific molecule according to claim 1 for use in the activation of T cells against DLL3 expressing cells. 請求項１に記載の前記二重特異性分子をコードするヌクレオチド。A nucleotide encoding the bispecific molecule of claim 1. ＣＤ３、ＣＤ２８又はＣＤ１３７を活性化するアゴニスト抗体と対を形成したＤＬＬ３に結合する抗体であって、
（１）配列番号７に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１４に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２７に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３１に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４０に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号４７に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（２）配列番号１に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１１に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２２に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３２に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号３９に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号５４に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（３）配列番号６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２４に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号４９に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（４）配列番号５に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２４に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号４９に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（５）配列番号２に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１０に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２２に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３２に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４６に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号５５に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（６）配列番号１に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１１に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２２に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３と、配列番号３２に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４６に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号５５に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（７）配列番号３に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１３に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２８に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３２に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４６に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号５４に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（８）配列番号６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１５に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２５に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号５１に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（９）配列番号６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２５に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号５１に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（１０）配列番号６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１８に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２５に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号５１に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（１１）配列番号６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２５に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号５１に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（１２）配列番号６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１５に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２４に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３４に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号４９に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（１３）配列番号６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１６に記載のアミノ酸配列を少なくとも含むＣＤＲ２、及び配列番号２４に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３４に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号４９に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（１４）配列番号６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１８に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２４に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３４に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号４９に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（１５）配列番号６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２４に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３４に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号４９に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（１６）配列番号６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１５に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２５に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３７に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４２に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号５１に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（１７）配列番号６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２５に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３７に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４２に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号５１に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（１８）配列番号６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１８に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２５に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３７に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４２に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号５１に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（１９）配列番号６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２５に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３７に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４２に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号５１に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（２０）配列番号７に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１５に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２４に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３８に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４２に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号４９に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（２１）配列番号６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２４に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３８に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４２に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号４９に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（２２）配列番号６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１８に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２４に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３８に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４２に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号４９に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（２３）配列番号６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２４に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３８に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４２に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号４９に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（２４）配列番号５に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２５に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号５１に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（２５）配列番号５に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２４に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３４に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号５０に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（２６）配列番号５に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１７に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２６に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３４に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４３に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号５０に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；
（２７）配列番号８に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号１９に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２３に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３５に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号４５に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号５２に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体；及び
（２８）配列番号９に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ１、配列番号２１に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ２、及び配列番号２９に記載のアミノ酸配列を少なくとも含む重鎖ＣＤＲ３を含む重鎖可変領域と、配列番号３２に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ１、配列番号３９に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ２、及び配列番号５４に記載のアミノ酸配列を少なくとも含む軽鎖ＣＤＲ３を含む軽鎖可変領域とを含む抗体
からなる群から選択される抗体。 An antibody that binds to DLL3 paired with an agonist antibody that activates CD3, CD28 or CD137,
(1) Contains a heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 7, a heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 14, and a heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 27. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 31, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 40, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 47. an antibody comprising a light chain variable region comprising CDR3;
(2) Contains a heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 1, a heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 11, and a heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 22. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 32, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 39, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 54. an antibody comprising a light chain variable region comprising CDR3;
(3) Contains heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 6, heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 16, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 24. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 33, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 43, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 49. an antibody comprising a light chain variable region comprising CDR3;
(4) Contains a heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 5, a heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 16, and a heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 24. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 33, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 43, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 49. an antibody comprising a light chain variable region comprising CDR3;
(5) Contains a heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 2, a heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 10, and a heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 22. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 32, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 46, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 55. an antibody comprising a light chain variable region comprising CDR3;
(6) heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 1, heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 11, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 22; A light chain variable comprising a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 32, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 46, and a light chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 55. an antibody comprising a region;
(7) Heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 3, heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 13, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 28. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 32, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 46, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 54. an antibody comprising a light chain variable region comprising CDR3;
(8) Heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 6, heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 15, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 25. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 33, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 43, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 51. an antibody comprising a light chain variable region comprising CDR3;
(9) Heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 6, heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 16, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 25. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 33, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 43, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 51. an antibody comprising a light chain variable region comprising CDR3;
(10) Heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 6, heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 18, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 25. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 33, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 43, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 51. an antibody comprising a light chain variable region comprising CDR3;
(11) Heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 6, heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 16, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 25. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 33, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 43, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 51. an antibody comprising a light chain variable region comprising CDR3;
(12) Heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 6, heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 15, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 24. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 34, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 43, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 49. an antibody comprising a light chain variable region comprising CDR3;
(13) Heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 6, CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 16, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 24. A variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 34, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 43, and a light chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 49. an antibody comprising a light chain variable region;
(14) Heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 6, heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 18, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 24. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 34, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 43, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 49. an antibody comprising a light chain variable region comprising CDR3;
(15) Heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 6, heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 16, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 24. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 34, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 43, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 49. an antibody comprising a light chain variable region comprising CDR3;
(16) Heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 6, heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 15, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 25. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 37, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 42, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 51. an antibody comprising a light chain variable region comprising CDR3;
(17) Heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 6, heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 16, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 25. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 37, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 42, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 51. an antibody comprising a light chain variable region comprising CDR3;
(18) Heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 6, heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 18, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 25. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 37, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 42, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 51. an antibody comprising a light chain variable region comprising CDR3;
(19) Heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 6, heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 16, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 25. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 37, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 42, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 51. an antibody comprising a light chain variable region comprising CDR3;
(20) Heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 7, heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 15, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 24. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 38, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 42, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 49. an antibody comprising a light chain variable region comprising CDR3;
(21) includes a heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 6, a heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 16, and a heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 24. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 38, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 42, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 49. an antibody comprising a light chain variable region comprising CDR3;
(22) includes a heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 6, a heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 18, and a heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 24. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 38, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 42, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 49. an antibody comprising a light chain variable region comprising CDR3;
(23) Heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 6, heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 16, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 24. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 38, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 42, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 49. an antibody comprising a light chain variable region comprising CDR3;
(24) includes a heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 5, a heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 16, and a heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 25. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 33, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 43, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 51. an antibody comprising a light chain variable region comprising CDR3;
(25) includes a heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 5, a heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 16, and a heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 24. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 34, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 43, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 50. an antibody comprising a light chain variable region comprising CDR3;
(26) includes a heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 5, a heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 17, and a heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 26. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 34, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 43, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 50. an antibody comprising a light chain variable region comprising CDR3;
(27) Heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 8, heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 19, and heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 23. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 35, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 45, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 52. an antibody comprising a light chain variable region comprising CDR3; and
(28) includes a heavy chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 9, a heavy chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 21, and a heavy chain CDR3 comprising at least the amino acid sequence set forth in SEQ ID NO: 29. A heavy chain variable region, a light chain CDR1 comprising at least the amino acid sequence set forth in SEQ ID NO: 32, a light chain CDR2 comprising at least the amino acid sequence set forth in SEQ ID NO: 39, and a light chain comprising at least the amino acid sequence set forth in SEQ ID NO: 54. and a light chain variable region comprising CDR3. そのＣＤＲドメインが、変異している、欠失している、又は付加されている１、２、３、４又は５個のアミノ酸を有する、請求項１４に記載の抗体。 15. The antibody of claim 14 , wherein the CDR domain has 1, 2, 3, 4 or 5 amino acids mutated, deleted or added. 前記抗体がヒト化されている、請求項１４に記載の抗体。 15. The antibody of claim 14 , wherein said antibody is humanized. ａ）請求項１４に記載の抗体、及び
ｂ）薬学的に許容される担体
を含む組成物。 15. A composition comprising a) an antibody according to claim 14 , and b) a pharmaceutically acceptable carrier . ＤＬＬ３発現細胞に対するＴ細胞の活性化において使用するための、請求項１４に記載の抗体を含む医薬組成物。 15. A pharmaceutical composition comprising an antibody according to claim 14 for use in the activation of T cells against DLL3 expressing cells. 癌治療において使用するための、請求項１４に記載の抗体を含む医薬組成物。 15. A pharmaceutical composition comprising an antibody according to claim 14 for use in cancer therapy . 配列番号５８又は７２と少なくとも９５％、少なくとも９６％、少なくとも９７％、少なくとも９８％、少なくとも９９％、又は少なくとも１００％の配列同一性を有する重鎖可変ドメインを含むヒトＤＬＬ３タンパク質に結合するヒト化抗体。 A humanized human DLL3 protein that binds to a heavy chain variable domain that has at least 95 %, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity with SEQ ID NO: 58 or 72. antibody. 配列番号７６又は７８と少なくとも９５％、少なくとも９６％、少なくとも９７％、少なくとも９８％、少なくとも９９％、又は少なくとも１００％の配列同一性を有する軽鎖可変ドメインを含むヒトＤＬＬ３タンパク質に結合するヒト化抗体。 A humanized human DLL3 protein that binds to a light chain variable domain that has at least 95 %, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity with SEQ ID NO: 76 or 78. antibody. 配列番号５８又は７２と少なくとも９５％、少なくとも９６％、少なくとも９７％、少なくとも９８％、少なくとも９９％、又は少なくとも１００％の配列同一性を有するアミノ酸配列を含むヒト化ヒトＤＬＬ３抗体重鎖をコードする核酸配列。 Encodes a humanized human DLL3 antibody heavy chain comprising an amino acid sequence having at least 95 %, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity to SEQ ID NO: 58 or 72 Nucleic acid sequences. 配列番号７６又は７８と少なくとも９５％、少なくとも９６％、少なくとも９７％、少なくとも９８％、少なくとも９９％、又は少なくとも１００％の配列同一性を有するアミノ酸配列を含むヒト化ヒトＤＬＬ３抗体軽鎖をコードする核酸配列。
 Encodes a humanized human DLL3 antibody light chain comprising an amino acid sequence having at least 95 %, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% sequence identity to SEQ ID NO: 76 or 78 Nucleic acid sequences.
JP2022547063A 2020-01-31 2021-02-01 Bispecific T cell engager Pending JP2023512297A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062968999P 2020-01-31 2020-01-31
US62/968,999 2020-01-31
PCT/US2021/016104 WO2021155380A1 (en) 2020-01-31 2021-02-01 Bispecific t cell engagers

Publications (2)

Publication Number Publication Date
JP2023512297A JP2023512297A (en) 2023-03-24
JPWO2021155380A5 true JPWO2021155380A5 (en) 2024-02-08

Family

ID=77079996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022547063A Pending JP2023512297A (en) 2020-01-31 2021-02-01 Bispecific T cell engager

Country Status (7)

Country Link
US (1) US11976133B2 (en)
EP (1) EP4097135A1 (en)
JP (1) JP2023512297A (en)
KR (1) KR20220162690A (en)
CN (1) CN115643806A (en)
AU (1) AU2021213840A1 (en)
WO (1) WO2021155380A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021173307A1 (en) * 2020-02-25 2021-09-02 Gensun Biopharma Inc. Trispecific t cell engagers
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
TW202342534A (en) * 2022-02-10 2023-11-01 大陸商上海齊魯製藥研究中心有限公司 A bispecific antigen-binding molecule and use thereof
WO2023164474A1 (en) 2022-02-23 2023-08-31 Amgen Inc. Cancer treatment targeting dll3
WO2023196953A2 (en) * 2022-04-08 2023-10-12 The Wistar Institute Of Anatomy And Biology Combinations of bispecific t cell engagers and methods of use thereof
WO2023204290A1 (en) * 2022-04-21 2023-10-26 愛知県 Multispecific nanoparticle
WO2023222135A1 (en) * 2022-05-20 2023-11-23 I-Mab Biopharma Co., Ltd. A method of treating solid tumor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6130097B2 (en) * 2008-10-01 2017-05-17 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー PSCA × CD3, CD19 × CD3, C-MET × CD3, endosialin × CD3, EpCAM × CD3, IGF-1R × CD3, or FAPalpha × CD3 cross-species specific bispecific single chain antibody
CA2894879A1 (en) * 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
GB201302447D0 (en) * 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
MA41613A (en) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc ANTI-DLL3 CHEMERICAL ANTIGENIC RECEPTORS AND METHODS FOR USING SUCH RECEIVERS
TWI793062B (en) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Antibody constructs for dll3 and cd3
TW202016151A (en) * 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 Multi-specific binding proteins for cancer treatment

Similar Documents

Publication Publication Date Title
JP2017186337A5 (en)
ES2879799T3 (en) Anti-HER2 antibody and conjugate thereof
RU2019123613A (en) BISPECIFIC ANTIGENBINDING MOLECULES CONTAINING ANTIBODY K4-1BB, CLONE 20N4.9
IL302078A (en) Anti-ccr8 monoclonal antibodies and uses thereof
JP2020525032A5 (en)
WO2019024911A1 (en) B7h3 antibody-drug conjugate and medical use thereof
CN107001468A (en) CD3 binding structural domains
JP7399852B2 (en) Multispecific antibodies and their production and use methods
JP2010535713A5 (en)
CA2691075C (en) Treatment of tumors using specific anti-l1 antibody
JP2010504755A5 (en)
EP3693389A1 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
JP2021530251A (en) New antibodies and methods for preparing and using them
CN113330034A (en) Monoclonal antibodies directed against the IgV domain of B7-H3 and uses thereof
JP2024016024A5 (en)
WO2021098822A1 (en) Bispecific antibodies
EP4069298A1 (en) Composition of triaxial antibodies and method of making and using thereof
IL310938A (en) Anti-ccr8 antibodies and uses thereof
JP2020523414A (en) Antibody drug conjugates that bind to LGR5
Hong et al. Chemoenzymatic Synthesis of a Rhamnose‐Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy
JPWO2021155380A5 (en)
CN115698072A (en) anti-GPC 3 antibody, anti-GPC 3 chimeric antigen receptor, and GPC3/CD3 bispecific antibody
WO2019157973A1 (en) Anti-trailr2 antibody-toxin-conjugate and pharmaceutical use thereof in anti-tumor therapy
JPWO2021168303A5 (en)
JPWO2021053587A5 (en)